Results 91 to 100 of about 208,963 (249)
Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India
Parasites & Vectors, 2017 BackgroundMiltefosine unresponsive and relapse cases of visceral leishmaniasis (VL) are increasingly being reported. However, there has been no laboratory confirmed reports of miltefosine resistance in VL.
Saumya S. Srivastava +5 more
semanticscholar +1 more source
Public Health Challenges, Volume 4, Issue 2, June 2025.An update on the composition and distribution of sand fly species in the Nile environments of Khartoum. Variations were observed in species number than in species composition. The study will be a good reference for future studies on sandflies after the change in their habitat due to the current war in Sudan. ABSTRACT Phlebotomine sand flies are vectors
Suhaib A. Gumaa +3 more
wiley +1 more source
HIV-associated visceral leishmaniasis [PDF]
Clinical Microbiology and Infection, 2001 Visceral leishmaniasis (VL) is a severe disease caused by protozoa of the genus Leishmania that usually affects immunocompetent hosts in endemic areas [1,2]. Since the mid-1980s, VL has been recognized as an opportunistic infection associated with some immunodeficiency states, such as neoplasms, organ transplantation, or treatment with ...
Vicente Pintado, R. López-Vélez
openaire +3 more sources
A case report on para-kala-azar dermal leishmaniasis: an unresolved mystery
BMC Infectious Diseases, 2023 Background Post-kala-azar dermal leishmaniasis (PKDL) is a dermatosis that occurs 2–3 years after an apparently successful treatment of visceral leishmaniasis (VL).
Md. Mehedi Hasan +6 more
doaj +1 more source
Declining Visceral Leishmaniasis in Malta [PDF]
, 2008 Aims: To study visceral leishmaniasis (VL) trends in Malta. Methods: Analysis of epidemiological and clinical trends, a veterinary questionnaire and questioning a canine laboratory testing facility.
Grech, Victor E., Vella, Cecil
core
ChemistrySelect, Volume 10, Issue 21, June 4, 2025.Leishmaniasis affects over 1 billion people worldwide, with current treatments limited by toxicity and efficacy. This study used machine learning (ML), QSAR, and polypharmacology to identify potential drug candidates, analyzing 12,072 compounds with random forest and XGBoost models.
Laís Salvador do Amaral +7 more
wiley +1 more source
Visceral leishmaniasis in eastern Africa--current status. [PDF]
, 2007 Visceral leishmaniasis (VL) is among the most neglected of the tropical diseases, afflicting the poorest of the poor. In eastern Africa, VL causes at least 4000 deaths annually, a loss of approximately 385,000 disability-adjusted life years.
Brooker, Simon +2 more
core +2 more sources
Infectious Diseases of Poverty, 2016 Visceral leishmaniasis (VL) is a serious parasitic disease causing considerable mortality and major disability in the Indian subcontinent. It is most neglected tropical disease, particularly in terms of new drug development for the lack of financial ...
O. Singh +3 more
semanticscholar +1 more source
Mesenchymal Stem Cells: A Double‐Edged Approach for Managing Cutaneous Leishmaniasis Lesions
International Wound Journal, Volume 22, Issue 6, June 2025.ABSTRACT Leishmania spp. are intracellular protozoan parasites responsible for leishmaniasis, a globally prevalent vector‐borne disease transmitted by phlebotomine sandflies. Within vertebrate hosts, the parasites preferentially infect macrophages and dendritic cells, leading to cell lysis and the formation of disfiguring lesions.
Masoud Foroutan +8 more
wiley +1 more source
Interventions for visceral leishmaniasis
Cochrane Database of Systematic Reviews, 2010 Reason for withdrawal from publication This protocol is being withdrawn from The Cochrane Library. The authors have made no progress with this protocol in seven years. The protocol is out of date and does not meet the current methodological standards of Cochrane.
Urbà González +6 more
openaire +3 more sources